Skip to content
Screener

LivaNova LIVN Cardiopulmonary — Operating Income

Other segment segments

Neuromodulation
$60.94M+8.8%

Similar metrics at other companies

Lincoln Educational Services Corporation logo
LINCCampus Operations — Operating Income
$27.73M+28.0%
DWS
DWSNCanada Operations — Operating Income
$5.4M-2.8%
Southern Copper logo
SCCOPeruvian Operations — Operating Income
$923.7M+64.5%
Falcon's Beyond Global logo
FBYDDestination Operations — Operating Income
-$242K+36.3%
Erie Indemnity Company logo
ERIEManagement Operations — Operating Income
$166.79M+10.2%
Universal Corporation logo
UVVIngredients Operations — Operating Income
$1.82M-58.5%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cardiopulmonary$28,152$31,407$58,219$56,098
Neuromodulation60,93556,020105,089108,373
Segment income89,08787,427163,308164,471
Other expense(39,603)(33,244)(72,353)(61,671)
Operating income49,48454,18390,955102,800
SNIA environmental liability expense—(1,677)—(362,070)
Interest expense (1)(7,176)(14,931)(15,467)(30,217)
Foreign exchange and other income/(expense)(23,829)(4,255)(29,524)7,161

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's cardiopulmonary — operating income?
LivaNova (LIVN) reported cardiopulmonary — operating income of $28.15M in Q2 2026.
How has LivaNova's cardiopulmonary — operating income changed year-over-year?
LivaNova's cardiopulmonary — operating income decreased by 10.4% year-over-year, from $31.41M to $28.15M.
What is the long-term trend for LivaNova's cardiopulmonary — operating income?
Over 3 years (2021 to 2025), LivaNova's cardiopulmonary — operating income has grown at a 156.3% compound annual growth rate (CAGR), from -$6.43M to $108.3M.
What does cardiopulmonary — operating income mean?
Measures the profitability of the cardiopulmonary segment by subtracting operating expenses, such as cost of sales and SG&A, from net revenue. It reflects the operational efficiency and core earnings power of the segment before interest and taxes.

Ask your AI about LivaNova's cardiopulmonary — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude